Magnetic Resonance Imaging Study of Geriatric Depression

This study is currently recruiting participants.

Verified by Mclean Hospital, September 2005

First Received: October 27, 2005 Last Updated: November 22, 2005 History of Changes

Sponsors and Collaborators:	Mclean Hospital Pfizer National Alliance for Research on Schizophrenia and Depression
Information provided by:	Mclean Hospital
ClinicalTrials.gov Identifier:	NCT00245557

Purpose

The purpose of this study is to use Magnetic Resonance Images to further our understanding of predictors and markers of treatment response and non-response in geriatric depression. We hypothesize that concentrations of high energy metabolites will be lower in depressed elderly compared to non-depressed.

Condition	Intervention
Major Depressive Disorder	Drug: Sertraline

MedlinePlus related topics: Depression MRI Scans

Drug Information available for: Sertraline hydrochloride Sertraline

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Historical Control, Factorial Assignment
Official Title:	Nuclear Magnetic Resonance Imaging Study of Treatment With Sertraline in Geriatric Depression

Further study details as provided by Mclean Hospital:

Primary Outcome Measures:

HAM-D weekly
Geriatric Depression Scale weekly
MRS at week 13

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	60 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

DSM- IV diagnositc criteria for major depressive disorder
Hamilton Depression Scale- 17 item version score of 18 or higher
Must speak English
Women must be post-menopausal

Exclusion Criteria:

A current or pervious psychiatric disorder other than MDD
A current unstable medical condition
A pacemaker or metal implant
History of alcohol or drug dependence or abuse within the past year
Current prescription of excluded medications
Use of a drug within the last 30 days that was not approved for use by governmental authorities.
If you or a family member works at McLean Hospital

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00245557

Contacts

Contact: Tom Cooper, B.A.	(617) 855-2410	tcooper@mclean.harvard.edu
Contact: Yossi Berlow, B.S.	(617) 855-3230	yberlow@mclean.harvard.edu

Locations

United States, Massachusetts
McLean Hospital	Recruiting
Belmont, Massachusetts, United States, 02478
Contact: Tom Cooper, B.A. 617-855-2410 tcooper@mclean.harvard.edu
Principal Investigator: Brent Forester, M.D.

Sponsors and Collaborators

Mclean Hospital

Pfizer

National Alliance for Research on Schizophrenia and Depression

Investigators

Principal Investigator:

Brent Forester, M.D

Mclean Hospital

More Information

No publications provided

Study ID Numbers:	2004P-002540
Study First Received:	October 27, 2005
Last Updated:	November 22, 2005
ClinicalTrials.gov Identifier:	NCT00245557 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Mclean Hospital:

Depression
Geriatric
MRI
Sertraline

Study placed in the following topic categories:

Neurotransmitter Agents
Depression
Mental Disorders
Psychotropic Drugs
Mood Disorders
Sertraline

Depressive Disorder, Major
Depressive Disorder
Serotonin Uptake Inhibitors
Serotonin
Antidepressive Agents
Behavioral Symptoms

Additional relevant MeSH terms:

Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Depression
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Depressive Disorder, Major
Depressive Disorder
Serotonin Uptake Inhibitors

Pharmacologic Actions
Behavioral Symptoms
Serotonin Agents
Mental Disorders
Therapeutic Uses
Mood Disorders
Sertraline
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on May 07, 2009